AbbVievsLakefront Biotherapeutics

ABBV and LKFT stock compared: price, dividend, valuation and results, from SEC filings.

LKFT

Lakefront Biotherapeutics

$33.31

Value $2.2B

-0.24%
LKFT's page

AbbVie (ABBV) has a market value of $506B and Lakefront Biotherapeutics (LKFT) $2.2B. Over the last year, with dividends, ABBV moved +26.6% and LKFT +9.2%. The P/E is 49.2 for ABBV and 5.8 for LKFT. Dividend yield: ABBV 2.42%, LKFT none.

At a glance

The main figures of both. A bar only shows which number is larger, not which is better.

  • Market value

    ABBV$506B

    LKFT$2.2B

    ABBV is 231 times LKFT

  • Revenue, 12 months

    ABBV$66.0B

    LKFT$1.3B

    ABBV is 51 times LKFT

  • Net income, 12 months

    ABBV$10.3B

    LKFT$377M

    ABBV is 27 times LKFT

  • Operating margin

    ABBV32.2%

    LKFT26.5%

    5.7 points apart

  • ROIC

    ABBV25.7%

    LKFT7.2%

    18.5 points apart

  • P/E

    ABBV49.2

    LKFT5.8

    ABBV is 8.4 times LKFT

  • Dividend yield

    ABBV2.4%

    LKFT0.0%

    2.4 points apart

  • 5-year return

    ABBV+194.4%

    LKFT-35.3%

    229.7 points apart

A fainter bar means a negative number. The 5-year return includes dividends.

The price over time

Both start at 100 at the beginning of the period, so the lines show how much each changed. With dividends means each dividend buys more shares.

ABBV+194.4%

LKFT-35.3%

10020030020222023202420252026
Returns by period
PeriodABBVWith dividendsLKFTWith dividends
1 year since November 19, 2025+26.6%Price +22.9%+9.2%Price +9.2%
3 years since November 20, 2023+128.8%+31.8% a yearPrice +106.9%-10.9%-3.8% a yearPrice -10.9%
5 years since November 19, 2021+194.4%+24.1% a yearPrice +146.2%-35.3%-8.3% a yearPrice -35.3%
10 years since November 22, 2016+630.1%+22.0% a yearPrice +385.7%-42.5%-5.4% a yearPrice -42.5%

Each cell: the total return with dividends, its yearly rate, and the price change alone. Before taxes and costs. Past returns do not predict future ones.

Every figure

As on each company's page. A description, not a recommendation: no one figure says which is better.

ABBVAbbVieLKFTLakefront Biotherapeutics

Valuation

ABBVLKFT
Valuation
Price$286.20$33.31
Market value$506B$2.2B
Enterprise value (EV)$576B$2.1B
P/E49.25.8
P/E, 5-year median57.011.5
P/B–0.6
EV/EBIT27.16.1
Free cash flow yield3.7%–

Results and growth

ABBVLKFT
Results and growth
Revenue, 12 months$66.0B$1.3B
Net income, 12 months$10.3B$377M
Free cash flow, 12 months$18.9B-$318M
Earnings per share, 12 months$5.81$5.72
Revenue growth, year on year8.6%303.5%
Revenue growth a year, past+5.9%over 5 years+18.4%over 5 years
EPS growth a year, past-2.8%over 5 years–

Margins and returns on capital

ABBVLKFT
Margins and returns on capital
Gross margin73.7%97.3%
Operating margin32.2%26.5%
Net margin15.7%28.8%
ROIC25.7%7.2%
ROE–9.9%

Balance sheet

ABBVLKFT
Balance sheet
Cash$10.8B$103M
Total debt$80.9B$8.1M
Net debt / EBITDA3.2–
Interest cover7.1×–

Dividends and buybacks

ABBVLKFT
Dividends and buybacks
Dividend yield2.4%–
Dividend per share, 12 months$6.92–
Dividend growth a year, past+6.6%over 5 years–
Buyback yield0.2%–
Shareholder yield2.6%–

Last 12 months from the latest 10-Q and 10-K. Value, P/E and yields at today's price. A dash means the figure does not exist or did not pass our checks.

Questions: ABBV or LKFT

Didn't find what you were looking for?

Ask us
Which is bigger, AbbVie or Lakefront Biotherapeutics?

By market value, AbbVie ($506B) is about 230.5 times Lakefront Biotherapeutics ($2.2B), at today's prices.

How did ABBV and LKFT stock do over the last 10 years?

Since November 22, 2016, ABBV's price moved +385.7% and LKFT's -42.5%. With dividends: ABBV +630.1% (+22.0% a year), LKFT -42.5% (-5.4% a year). Past returns do not predict future ones.

Which pays the higher dividend, ABBV or LKFT?

The dividend yield at today's price is 2.42% for AbbVie and none for Lakefront Biotherapeutics. Over the last twelve months they paid $6.92 and – per share.

What is the P/E of ABBV and LKFT?

At today's price, the P/E is 49.2 for ABBV and 5.8 for LKFT. The median of the last five years was 57.0 and 11.5, which shows where each stands against its own past.

Which has the higher profit margins, AbbVie or Lakefront Biotherapeutics?

Over the last twelve months, the net margin was 15.7% for AbbVie and 28.8% for Lakefront Biotherapeutics, and the operating margin 32.2% and 26.5%. Revenue was $66.0B and $1.3B.

Which is the better investment, AbbVie or Lakefront Biotherapeutics?

The page does not answer that and does not suggest buying or selling. It puts the two companies' numbers side by side, from their SEC filings, for you to read and form your own view. The decision depends on your goals and situation.

Other comparisons

With each of the two, and with the largest in its sector.

Related pages

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

Descriptive data from SEC filings and market prices.